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ABSTRACT While the mammalian heart has low, but
functionally significant, levels of telomerase expres-
sion, the cellular population responsible remains in-
completely characterized. This study aimed to identify
the cell types responsible for cardiac telomerase activ-
ity in neonatal, adult, and cryoinjured adult hearts using
transgenic mice expressing green fluorescent protein
(GFP), driven by the promoter for murine telomerase
reverse transcriptase (mTert), which is a necessary and
rate-limiting component of telomerase. A rare popula-
tion of mTert-GFP-expressing cells was identified that
possessed all detectable cardiac telomerase RNA and
telomerase activity. It was heterogeneous and included
cells coexpressing markers of cardiomyocytic, endothe-
lial, and mesenchymal lineages, putative cardiac stem
cell markers, and, interestingly, cardiomyocytes with a
differentiated phenotype. Quantification using both
flow cytometry and immunofluorescence identified a
significant decline in mTert-GFP cells in adult animals
compared to neonates (;9- and ;20-fold, respec-
tively). Cardiac injury resulted in a ;6.45-fold expan-
sion of this population (P<0.005) compared with sham-
operated controls. This study identifies the cells
responsible for cardiac telomerase activity, demon-
strates a significant diminution with age but a marked
response to injury, and, given the relationship between
telomerase activity and stem cell populations, suggests
that they represent a potential target for further inves-
tigation of cardiac regenerative potential.—Richard-
son, G. D., Breault, D., Horrocks, G., Cormack, S.,
Hole, N., Owens, W. A. Telomerase expression in the
mammalian heart. FASEB J. 26, 4832–4840 (2012).
www.fasebj.org
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Telomerase is a ribonucleoprotein complex typi-
cally expressed in cellular populations capable of ex-
tended replication, such as germ cells, tumor cells, and
stem cells. It is best known for its ability to maintain the
telomeric ends of chromosomes, which are ordinarily
shortened with cell division, leading to cellular senes-
cence and death. Telomerase reverse transcriptase
(TERT) is the catalytic subunit of the telomerase com-
plex, is transcriptionally regulated (distinguishing it
from the other components of the complex) (1), and is
the rate-limiting component of telomerase activity
(ref.2; reviewed in ref. 3). Increasing evidence suggests
that TERT has functions in stem cell proliferation and
differentiation (4), including transcriptional regulation
of mitogenic and angiogenic genes (5, 6). TERT also
binds mitochondrial DNA and has functions in cell
respiration, apoptosis, and protection against oxidative
stress (7).
Cardiac telomerase activity is detectable at the earli-
est stages of life and is down-regulated in adult rat
myocardium (8). Evidence points to an important role
for telomerase activity in the development and function
of the normal heart; TERC2/2 mice that lack telomer-
ase function develop cardiac abnormalities, including
dilated cardiomyopathy and reduced angiogenic poten-
tial (reviewed in ref. 9). In contrast, forced telomerase
expression leads to prolonged cardiomyocyte cycling
and hypertrophy (10). Telomere dysfunction in the
cardiac stem cell population is suggested to be a
contributing factor to hearts suffering from aging and
end-stage failure in mice and dogs (11–13). Telomerase
activity has been used as a defining feature of stem cell
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populations and demonstrated in some descriptions of
putative cardiac stem cells (14).
Demonstration of TERT expression and the source
of cardiac telomerase activity is challenging. The telo-
meric repeat amplification protocol (TRAP) assay,
while specific, is limited in sensitivity, which can be
exacerbated by the effects of tissue digestion and cell
sorting. This is important in antigenically defined car-
diac stem cell populations, where cell numbers are
typically low. While immunohistochemistry is an ap-
pealing alternative, there is controversy regarding the
specificity of antibodies (15).
To enable the identification and isolation of TERT
mRNA-expressing cells in vivo, we previously generated
a transgenic mouse, in which the murine TERT (mTert)
promoter drives green fluorescent protein (GFP) ex-
pression. In this model, mTert-GFP expression marks
telomerase activity within embryonic, hematopoietic,
and intestinal stem cells, germ cells (16–18), and
induced pluripotent stem (iPS) cells (19). We hypoth-
esized that it would enable the in vivo identification of
the population responsible for the telomerase activity
previously described in cardiac tissue, with the potential
to demonstrate whether these cells have a role in a
cardiac regenerative response to injury.
We identified an infrequent population of nonhema-
topoietic cells in the heart containing all of the detect-
able telomerase activity. This population was found in
the highest quantity in the neonatal heart and declined
on maturation to adulthood. Immunofluorescent stud-
ies demonstrated that mTert is expressed in a number of
different cell lineages, including those expressing rec-
ognized stem cell characteristics. Although mTert-ex-
pressing cells are extremely rare in the adult heart
(;0.012%), there was a localized increase in the num-
ber of mTert-GFP cells in the response to an acute
myocardial injury.
This study provides a comprehensive description of
the cell types responsible for telomerase activity in the
heart in vivo. Further examination of this population
will provide a better understanding of the function of
both telomerase activity and TERT signaling in the
heart.
MATERIALS AND METHODS
Ethics statement
Ethical approval of animal work carried out in this project has
been authorized by the Newcastle University Ethics Commit-
tee and was covered by Project License PPL/60-3876, ap-
proved by the UK Home Office.
Transgenic animals
Generation and initial phenotypic characterization of the
mTert-GFP mice have been published previously (17–19).
Cardiac cell harvesting
Hearts were removed from adult and neonatal animals killed
by approved methods, finely minced, and incubated at 37°C
for 30 min in MEM containing collagenase II (0.1%; Wor-
thington Biochemical, Lakewood, NJ, USA) and DNase (0.6
mg/ml) to disaggregate into a single-cell suspension. Red
blood cells were depleted with red blood cell lysis buffer.
Flow cytometry and mTert-GFP quantification
Native GFP expression was detectable by flow cytometry
without the need for antibody labeling. For all flow cytometry
experiments, the mouse lineage antibody cocktail (BD
Pharmingen, Oxford, UK) specific to CD3e chain, CD11b,
CD45R/B220, and erythroid cells (Ly-76/TER-119), Ly-6G,
and Ly-6C, was used to exclude contamination by hematopoi-
etic lineage. To exclude nonviable cells, 7-aminoactinomycin
D (7-AAD; BD Pharmingen) was added prior to flow cytom-
etery. Flow cytometry was performed using a FACSAria (BD
Biosystems, Oxford, UK). To characterize expression of pu-
tative stem cell antigens, cells were further labeled with
fluorochrome-conjugated antibodies specific to Sca-1/Ly6A/E
(clone D7-phycoerythrin). Expression analysis was per-
formed on a BD FACSCalibur (BD Biosystems), running
FlowJo software (Tree Star, Ashland, OR, USA). Hearts
from mTert-GFP transgenic animals were studied by flow
cytometry at postnatal day 3 (n54) and 3 mo (n526) and
12 mo of age (n56).
Reverse transcriptase–polymerase chain reaction (RT-PCR)
Equal numbers of hematopoietic lineage negative (Lin2),
GFP-expresssing (GFP1), and Lin2, GFP absent (GFP2)
viable, hematopoietic lineage-depleted cells were separated
from transgenic mTert-GFP neonatal hearts using flow
cytometry. mRNA was isolated, cDNA was transcribed, and
PCR was performed using Invitrogen PCR Supermix with
the following primers: TERT-F, 5=-GGATTGCCACTG-
GCTCCG-3=, and TERT-R, 5=-TGCCTGACCTCCTCTTGT-
GAC-3= (20); and GAPDH-F, 5=-TGTGCAGTGCCAGCC-
TCGTC-3=, and GAPDH-R, 5=-TGACCAGGCGCCCAATACGG-3=.
TRAP
Flow cytometry was used to isolate viable, hematopoietic
lineage-depleted cells from hearts and viable cells from the
bone marrow (n55) of mTert-GFP transgenic animals, and
these were subjected to TRAP using the TRAPeze RT telom-
erase detection kit (Millipore, Bedford, MA, USA), as per
manufacturer’s instructions. This assay quantifies telomerase
activity by measuring real-time fluorescence emission using
real-time quantitative RT-PCR (qRT-PCR). Cells (13104) for
each population were lysed in 20 ml of 3-[(3-cholamido-
propyl)dimethylammonio]-1-propanesulfonate (CHAPS) ly-
sis buffer. Telomerase activity, in terms of the addition of
telomeric repeats (GGTTAG) onto the 3= end of a substrate
oligonucleotide (TS) during an initial reaction, was then
calculated by real-time qRT-PCR. Relative values were calcu-
lated by comparing the average Ct values from each sample
against a standard curve generated using a TSR8 control
template. Telomerase-expressing cells (provided with the kit)
and GFP1 cells isolated from bone marrow, previously shown
to be telomerase active (17) served as a positive control, and
heat-inactivated cell extracts served as a negative control.
Assays were performed on an Applied Biosystems 7500 Fast
real-time PCR System (Applied Biosystems, Foster City, CA,
USA). The baseline was set to a no-TSR8 control.
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Immunofluorescence
Hearts were removed from freshly killed animals, fixed in 4%
paraformaldehyde in PBS at 4°C overnight, and cyropro-
tected with 30% sucrose in PBS. The samples were embedded
in TissueTek optimal cutting temperature (OCT) compound
(Agar Scientific, Essex, UK), snap-frozen in liquid nitrogen,
and stored at 280°C. Paraformaldehyde-fixed cryosections
(10 mm) were labeled with the primary antibodies, and
secondary Alexa Fluor-conjugated antibodies (Molecular
Probes; Invitrogen, Carlsbad, CA, USA) were used for detec-
tion. Primary antibody: anti-a-smooth muscle actin (a-SMA;
clone ab5694), anti-CD45 (clone ab19592), anti-C-kit (clone
ab5506), anti-GATA4 (phosphor S105; clone ab5245), anti-
GFP (clone ab6662), anti-islet 1 (clone ab20670), anti-Sca-1/
Ly6A/E (E13 161-7; clone ab51317), anti-cardiac troponin I
(CTnI; clone ab58544), and anti-vimentin (clone ab24525)
(Abcam, Cambridge, UK); anti-CD31 (PECAM-1; clone
Mec13.3; BD Pharmingen); anti-Nkx2.5 (clone H-114; Santa
Cruz Biotechnology; Autogen Bioclear, Wiltshire, UK); anti-
phospho-histone H3 (Ser10; Upstate, Millipore, Billerica,
MA, USA); anti-Ki67 (NCL-Ki67p; Novocastra, Newcastle-on-
Tyne, UK). Nuclei were labeled with 0.2 mg/ml 4=,6-di-
amidino-2-phenylindole (DAPI). For analysis, an Axioimager
M1 fluorescence microscope (Carl Zeiss, Oberkochen, Ger-
many) running OpenLab software (Improvision, Coventry,
UK) or the Leica SP5 laser-scanning confocal system (Leica
Microsystems, Wetzlar, Germany) was used. To rule out
staining artifacts creating false colocalization events, all pri-
mary and Alexa Fluor-conjugated secondary antibodies used
were also analyzed individually. The fluorescence signals for
each fluorochrome-conjugated antibody used was only ob-
served in the appropriate fluorescence channel. Colocaliza-
tion of multiple signals was verified by creating Z-stack images
using the Leica SP5 laser-scanning confocal system; cells were
only considered coexpressing if the fluorescent signals local-
ized to a single DAPI-labeled nucleus throughout the Z stack.
Specificity of all secondary antibodies and the absence of
autofluorescence were tested by omitting primary controls.
These controls gave undetectable background signal. For all
immunofluorescence studies, GFP signal was amplified using
an anti-GFP antibody. The specificity of this antibody was
evaluated on wild-type littermate controls. Wild-type cardiac
sections displayed no reactivity to this GFP antibody.
Adult mTert-GFP cell counts were performed in a manner
similar to the cellular counting method described by Walsh et
al. (21). Myocardial tissue was cryosectioned laterally in
10-mm sections. Sections were separated by intervals of 50 mm,
and all mTert-GFP-expressing cells were counted in each
section, creating a representative cross section that included
all regions of the heart. The percentage of GFP-expressing
cells was obtained by dividing the total number of GFP cells
per section by the total number of cells in each section; cells
were defined by the nucleus label DAPI. Quantification of
total nuclei was obtained by multiplying cell density by section
area. Both the density of nuclei and area of the section were
quantified using digital image analysis (ImageJ; U.S. National
Institutes of Health; http://rsbweb.nih.gov/ij/). Approxi-
mately 1.8 3 106 nuclei/heart with a total of 5.4 3 106 nuclei
analyzed for each antibody were investigated. The results are
presented as means 6 se. The significance of the differences
was determined with the use of Student’s t test. While this
method does not account for binucleation, as described by
Walsh et al. (21), it has the advantage of enabling more
extensive coexpression analyses, while still demonstrating
relative proportions of cell types and changes in them, if not
absolute numbers in individual hearts.
To assess expression of antigenic markers by mTert-GFP-
expressing cardiac cells, hematopoietic cells were excluded
from the analysis. Hearts from mTert-GFP animals were la-
beled with antibodies to GFP and CD45. No cells coexpress-
ing mTert-GFP and CD45 were detected in extravascular
tissues, and only a small number of mTert-GFP- and CD45-
coexpressing cells were observed within the lumen of the
larger blood vessels and the chambers of atria and ventricles.
The latter cells had typical mononucleocyte morphology,
suggestive of a hematopoietic lineage, and were excluded
from further analysis on this basis (Supplemental Fig. S6).
Induced myocardial cryoinjury
Myocardial cryoinjury was performed as described by Lefer-
ovich et al. (22). This model of injury, as opposed to coronary
ligation, was chosen aiming to generate a regenerative re-
sponse in a reproducible manner with low mortality, rather
than replicate a myocardial infarction per se, with the associ-
ated ischemic and pathophysiological phenomena. At 14 d
after the injury, the hearts were removed and analyzed by
immunofluorescence as described above. A total of 9 mTert-
GFP animals underwent cryoinjury; controls either under-
went a sham procedure (abdomen opened but no cryoinjury)
or did not undergo any surgical procedure. Quantification of
the mTert-GFP population in the injured and sham-injured
animal hearts was determined by immunofluorescence, as
described for adult hearts above.
Statistics
Data are presented as means 6 se. Groups were compared
using Student’s t test. When comparing multiple groups, data
were analyzed by analysis of variance (ANOVA). A value of
P , 0.05 was considered statistically significant.
RESULTS
mTert mRNA expression and telomerase activity are
restricted to the GFP-expressing population
Previous work has demonstrated that mTert-GFP expres-
sion correlates closely with the native mTert mRNA
transcripts and telomerase activity within all tissue
systems investigated (17–19). We sought to confirm
that GFP transgene expression maps to mTert mRNA
expression and telomerase activity in Lin2 cardiac cells.
Relative to a housekeeping gene, Lin2, GFP1 cells
exhibited the highest levels of mTert transcript, whereas
no mTert mRNA expression was observed in the Lin2,
GFP2 population (Fig. 1A). mTert mRNA expression
was also analyzed in digested but unsorted mTert-GFP
transgenic hearts. In unsorted heart cells, expression
was low but detectable. TRAP demonstrated that telom-
erase activity was restricted to the GFP1 population of
Lin2 cardiac cells; telomerase activity in the Lin2,
GFP1 cardiac population was at a level comparable to
that of GFP1 bone marrow cells, previously identified as
containing all bone marrow telomerase and stem cell
activity (17). Telomerase activity was undetectable in
the GFP2 cardiac population (Fig. 1B).
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mTert-GFP is expressed in cell populations in the
heart that change in proportion over 12 mo
We investigated changes in the number of mTert-ex-
pressing cells in the hearts from mTert-GFP transgenic
animals by flow cytometry at 3 d, 3 mo, and 12 mo of
age (Fig. 2A). The Lin2 population accounted for
;98% of total cells at all ages. At 3 d of age, 0.18 6
0.10% of the cardiac Lin2 cells expressed mTert-GFP;
this population decreased at 3 mo to 0.02 6 0.01%
(P,0.05), and the number of mTert-GFP-expressing
cells continued to decline to 0.01 6 0.01% at 12 mo
(not statistically significant).
Quantification by immunofluorescence identified
that 0.24 6 0.08% of cells (as defined in Materials
and Methods) in neonatal hearts expressed mTert-
GFP. In adult (.3 mo) mTert-GFP transgenic hearts,
this method demonstrated GFP expression in 0.012 6
0.003% of total cardiac cells.
Telomerase expression is associated with cellular
proliferation (23); however, in the intestinal crypt,
mTert expression identifies a population of slow-cycling
stem cells that generally lack expression of the prolif-
eration marker Ki67 (18). Therefore, we determined
expression of Ki67 and phospho-histone H3 (pHH3) in
mTert-expressing cells. In the neonatal heart, 0.75 6
0.25 and 1.4 6 0.35% of total cardiac cells expressed
pHH3 or Ki67, respectively. Although no mTert-GFP
cells were observed coexpressing pHH3 (Fig. 2B and
Supplemental Fig. S1), 5.71 6 1.63% coexpressed Ki67
(Fig. 2C and Supplemental Fig. S1). This may represent
the more restricted cell cycle expression of pHH3 than
Ki67 (24, 25). The Ki67 coexpression levels are consis-
tent with those in the intestine and suggest that, as in
the intestine, cardiac mTert-expressing cells are a largely
quiescent population.
mTert-GFP-expressing cells in the heart express a
range of antigenic markers
Ablation of telomerase activity influences the biology of
a number of cardiac lineages, reducing angiogenic
potential and resulting in abnormalities in cardiomyo-
cyte size, number, and proliferative potential, and
enhancing myocyte death (26). Therefore, we localized
and quantified mTert-GFP expression in relation to
lineage-specific antigens.
mTert-GFP1 cells coexpressing the cardiac transcrip-
tion factors Nkx2.5 or GATA4 were identified within
the myocardium (Fig. 3A, B). mTert-GFP1, GATA41, or
Nkx2.51 cells had morphologies ranging from cells
lacking sarcomeric structures to those of more mature
cardiomyocytes. Association with a cardiomyocytic lin-
eage was confirmed with CTnI coexpression. mTert-
GFP1 CTnI1 cells were observed in the compact layer
of each ventricle (Fig. 3C) and atrial wall (Fig. 3D). As
mTert-GFP1 cells were observed in the cardiac vascula-
ture, hearts were stained for CD31, a marker of endo-
thelial cells. mTert-GFP1 CD311 cells were identified
in two distinct locations: within the endothelial layer of
the lumen of the coronary vasculature (Fig. 3E) and
within the myocardium of the ventricular walls (Fig.
3F). The latter were round or oval-shaped, relatively
small, and otherwise featureless, with a large nuclear to
cytoplasmic ratio. A proportion of these cells had a
histological distribution, suggesting a relationship with
Figure 1. GFP expression maps to TERT transcripts and telomer-
ase activity in the heart. A) Comparison ofmTert mRNA expression
in Lin2, gated GFP1, and GFP2 cells compared to GAPDH.
Amplified product was assessed at 35 and 45 cycles to clarify
comparative expression. All products were of correct size. WH,
whole unsorted heart. B) Comparison of telomerase activity in
viable Lin2, GFP1, and GFP2 cells via real-time qPCR-based TRAP
assay. Bars represent means 6 se of $3 independent experiments.
Figure 2. A) Number of mTert-expressing cells is dynamic
during development and aging. FACS quantification of mTert-
expressing cells within the viable Lin2 populations in 3-d,
3-mo, and 12-mo GFP transgenic hearts. Bars represent
means 6 se of $4 independent experiments. B, C) mTert-GFP
expression is not restricted to actively cycling cells. Green,
mTert-GFP; red, pHH3 (B) or Ki67 (C); blue, DAPI (nuclei).
White arrows indicate GFP only; red arrows indicate Ki67 or
pHH3 only; yellow arrows indicate coexpression. Scale bars 5
25 mm.
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the smaller (CD31-expressing) vessels in the myocar-
dium. However, individual mTert-GFP1 CD311 cells
were also observed, which displayed no such associa-
tion.
With respect to the mesenchymal or fibroblast lin-
eages, mTert-GFP1 vimentin1 cells lacking expression
of CD31 were identified. mTert-GFP1 cells expressing
fibroblast-specific protein 1 were also identified (Sup-
plemental Fig. S2). These cells had a fibroblastic mor-
phology and were found in the atrial septum and
fibrous skeleton of the heart, related to the atrioven-
tricular valves (Fig. 3G).
Immunofluorescent analysis of adult hearts revealed
a similar profile in terms of the expression of markers
of the investigated lineages (Supplemental Fig. S3),
although with a reduced frequency.
Regardless of the antibody combinations used, mTert-
GFP1 cells were identified that failed to coexpress any
of the investigated antigens. These cells were distrib-
uted throughout the myocardium (Supplemental Fig.
S4A) and epicardium (Supplemental Fig. S4B).
These data demonstrate that the mTert-GFP cell pop-
ulation is heterogeneous and represents a very rare
subpopulation of cardiomyocytic, endothelial, and fi-
broblast lineages, including cells with a mature pheno-
type.
Cryoinjury to the adult myocardium is associated with
an increase in mTert-GFP-expressing cell numbers
We investigated mTert-GFP expression in myocardial
injury, using a cryoinjury model to generate a repro-
ducible injury with low mortality and enabling exami-
nation of mTert-GFP1 cells in a localized area sur-
rounded by relatively healthy myocardium.
At 14 d following cryoinjury, a distinct “injury zone”
was apparent where CTnI-expressing cardiomyocytes
had been destroyed with relatively normal tissue adja-
cent (Fig. 4A–D). This allowed identification of the area
of greatest cellular damage and comparisons between
the injury zone and the surrounding area.
Comparison of the total percentage of mTert-GFP1
cells in the cyroinjured hearts identified a significant
6.45-fold (P,0.005) increase compared to control
adult hearts (Figs. 4 and 5 and Supplemental Fig. S5).
Quantification of the mTert-GFP-expressing cells within
the injury zone demonstrated that 4.52 6 1.09% of cells
expressed GFP (Fig. 4E), an ;500-fold increase in
mTert-GFP-expressing cells when compared to the same
region in controls (P,0.005). No mTert-GFP1 cells were
found to costain with the hematopoietic marker CD45
(data not shown). mTert-GFP1 CD311 cells were iden-
tified both within vascular-like structures in the injury
zone (Fig. 5A–C) and as less structurally organized cells
throughout the injury zone (Fig. 5D). mTert-GFP1 Vim1
cells were also found in the injury zone (Fig. 5E). As in
the uninjured hearts, cells lacking the expression of all
investigated antigens were identified in the injury zone
and in the periphery of the injury (Fig. 5F).
Regarding cardiac transcription factors, mTert-GFP1
GATA41 and/or Nkx2.51 cells were identified in rela-
tion to the area of injury (Fig. 5G). Very infrequently,
cells that expressed CnTI in a sarcomeric pattern with
a low level of GFP expression were seen at the periph-
ery of the injury and within the injury zone (Fig. 5H and
Supplemental Fig. S5).
Figure 3. In the neonatal heart, mTert-GFP cells are a heter-
ogeneous population and express genes associated with car-
diomyocyte endothelial and fibroblastic lineages. A–D) mTert-
GFP1 NKx2.51 (A) and mTert-GFP1 GATA41 cells (B) within
myocardium, mTert-GFP1 CTnI1 cells in the ventricle (C),
and mTert-GFP1 CTnI1 cells in the atria (D). Insets: lower-
magnification images. E) Vascular structures expressing CD31
were identified containing mTert-GFP-expressing cells. F)
mTert-GFP
1
CD311-coexpressing cells in the myocardium. G)
mTert-GFP1 vimentin (Vim)1 cells in the atrioventricular
valve. Inset: lower-magnification image and the region of AV
shown in the main figure. Green, mTert-GFP; red, GATA4,
Nkx2.5, or CTnI; magenta, CD31 or vimentin; blue, DAPI
(nuclei). Yellow arrows indicate coexpressing cells. Scale
bars 5 25 mm.
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Relationship between mTert-GFP expression and
markers of putative cardiac stem cells
Within the heart, cells expressing Sca-1, c-kit, and Isl1
have been associated with cardiac stem cell activity. In
neonatal mTert-GFP transgenic hearts, cells coexpress-
Figure 4. Cryoinjured hearts contain a localized injury with an
increase in mTert-GFP-expressing cells. A) Heart at 14 d after
cryoinjury showing a localized injury with normal surround-
ing tissue. B) Unstained mouse heart demonstrating full
depth of the tissue damage. Injured tissue penetrated the
myocardium through to the ventricular cavity. C) Sham-
injured animals showed a consistent expression of CTnI
throughout the myocardium, CTnI only being absent from
the outermost epicardial cell layer. D) Hearts at 14 d after
cryoinjury had a localized injury zone (IZ) lacking CTnI
expression with adjacent subinjury zone (SI). Green, mTert-
GFP; red, CTnI; blue, DAPI (nuclei). Scale bars 5 250 mm. E)
Percentage of mTert-GFP cells in sham-injured and cyroin-
jured hearts at 14 d after injury. Values are means 6 se of $3
independent experiments.
Figure 5. In the adult heart, all mTert-GFP cell phenotypes de-
scribed in neonates were found at 14 d after cryoinjury. A) mTert-
GFP cells in the injury zone (IZ) and subinjury (SI) zone. B) In the
IZ, CD31 expression shows the presence of structures resembling
blood vessels, which contain mTert-GFP1 CD311 cells (yellow
arrows). Single mTert-GFP-expressing CD312 cells were also ob-
served in the epicardium and myocardium of the IZ, as well as the
SI zone (white arrows). C) Cryoinjured wild-type littermate controls
expressed a similar CD31 profile to mTert-GFP animals, but noGFP
reactivity was observed. D) mTert-GFP1 CTnI2 and mTert-GFP1
CD312 cells were observed in the SI myocardium. E, F) Higher-
magnification images of the IZ showing mTert-GFP1 Vim1 (E) and
mTert-GFP1 CD31 (F) cells. G) A population of mTert-GFP cells
within the IZ express cardiac transcription factors GATA4 and
Nkx2.5.H)Cells withmature cardiomyocytemorphologies express-
ing mTert-GFP and CTnI are found within the IZ (yellow arrows).
A–D) Green, mTert-GFP; red, CD31 or CTnI; blue, DAPI (nuclei).
E–F) Green, mTert-GFP; red, CTnI, a-SMA, GATA4, or Nkx2.5;
magenta, CD31 or vimentin; blue, DAPI (nuclei). White arrows
indicate mTert-GFP only; yellow arrows indicate mTert-GFP cells
coexpressing investigated markers. Scale bars 5 25 mm or as
indicated.
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ing mTert-GFP and Sca-1 were observed (Fig. 6A) and
quantified by fluorescence-activated cell sorting
(FACS) analysis. Sca-1-expressing and -nonexpressing
populations were identified within the Lin2 mTert-GFP-
expressing population. In 3-d-old neonates, 9.9 6 5.6%
of the mTert-GFP-expressing population coexpressed
Sca-1, significantly increasing to 26.0 6 6.6% (P,0.05)
at 3 mo of age, and subsequently significantly decreas-
ing to 15.5 6 0.9% (P,0.05) at 12 mo of age (Fig. 6B
and Supplemental Fig. S6). Although cells expressing
c-kit or Isl1 were observed in neonatal mTert-GFP
hearts, none expressing mTert-GFP were found (Supple-
mental Fig. S7B, C).
DISCUSSION
The use of this mTert-GFP reporter mouse enables the
demonstration of telomerase expression at a single-cell
level, overcoming the problems associated with conven-
tional immunohistochemistry. We demonstrate that in
the heart, mTert-GFP is expressed by a heterogeneous
population containing all detectable telomerase activity
and TERT mRNA and includes cells of endothelial,
fibroblast, and cardiomyocytic lineages, as well as pop-
ulations with characteristics of putative cardiac stem
cells. mTert-expressing cells were rare, in the order of
several hundred cells per heart, and highest in neo-
nates, indicating that the reported decrease in telom-
erase activity after birth (27) is at least in part due to
this reduction in mTert cell number. The demonstra-
tion of a marked, localized increase in number of
telomerase-expressing cells in response to injury in the
adult heart suggests a role for these cells in regenera-
tion.
It has been suggested that cardiac telomerase acti-
vity is restricted to cardiomyocytes. Cardiomyocyte-
enriched cultures, prepared by enzymatic digestion of
rat ventricle, were shown to possess telomerase activity
by PCR-TRAP assay, and an immunohistological ap-
proach using a canine model suggested that TERT is
expressed in a surprisingly high proportion of cardio-
myocytes but undetectable in cardiac endothelial cells
or fibroblasts (28). Earlier studies using the TRAP assay
failed to demonstrate telomerase activity in smooth
muscle and fibroblast cell lines (29). The presence of
telomerase activity in endothelial cells continues to be
debated (see ref. 30 for review).
Our data demonstrating mTert expression in endo-
thelial cells is consistent with other reports that identi-
fied low levels of telomerase expression in fresh endo-
thelial cultures (31, 32), confirming that they express
telomerase in vivo. The increase in CD31-coexpressing
cells following injury is consistent with an angiogenic
response, supported by studies demonstrating in-
creased endothelial Tert mRNA and telomerase activity
in response to FGF-2-induced proliferation (32). Stud-
ies are planned to characterize the role of telomerase-
expressing endothelial cells in angiogenesis.
With respect to fibroblasts, there is evidence that
quiescent fibroblasts possess low levels of telomerase
activity that increases in response to stimuli, for
example, with bleomycin-induced lung injury (33)
and reprogramming (19). In this study, cells with a
fibroblastic phenotype were observed to express
mTert; although infrequent in the normal heart, this
population was found in association with the fibrous
skeleton, the apparent fibroblastic response to injury
further suggested a mesenchymal lineage. Consistent
with the reported loss of telomerase expression on
myofibroblast differentiation, myofibroblasts, identi-
fied by a-SMA, did not demonstrate mTert-GFP ex-
pression (34).
Although this study contradicts the suggestion that
cardiac endothelial cells and fibroblasts do not express
telomerase, it is unlikely to significantly underestimate
total numbers of telomerase-expressing cells. Indepen-
dent methods of quantification demonstrate absolute
numbers with similar magnitudes, even when the inev-
itable cell loss associated with digestion and sorting is
taken into consideration. The lack of telomerase activ-
ity and RNA in the GFP2 population, and previous
validation of this model, suggests strongly that there is
unlikely to be a significant population of telomerase-
competent cells not expressing the transgene. Given
the low number of cells expressing fibroblast or endo-
thelial markers, particularly in adult hearts, failure to
identify them by conventional immunohistochemistry
or TRAP assays is unsurprising; the difference in num-
bers of telomerase-expressing cardiomyocytes may re-
Figure 6. Sca-1 is expressed in a subpopulation of
neonatal cardiac mTert-GFP-expressing cells. A)
mTert-GFP1 Sca-11 cells in the myocardium.
Green, mTert-GFP; red, Sca-1; magenta, vimentin;
blue, DAPI (nuclei). White arrow indicates mTert-
GFP only, yellow arrows indicate mTert-GFP and
Sca-1 coexpression. Scale bars 5 25 mm. B)
Quantification of Sca-1-coexpressing cells within
the viable Lin2 mTert1 population by flow cytom-
etry in mTert-GFP transgenic hearts at 3 d, 3 mo,
and 12 mo. NS, not significant. Data represent
means 6 sd of $4 independent experiments.
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flect issues of antibody specificity, species differences,
and/or the injury models used.
The localized expansion of populations of mTert-GFP-
expressing cells in the adult heart, together with the
fidelity of this model in the identification of stem cell
populations (17, 18), suggests a subpopulation of mTert
cells representing a stem or progenitor population.
This is reinforced by mTert-GFP expression found in
association with cardiac transcription factors NKX2.5
and GATA4, factors required for cardiomyocyte devel-
opment and previously described as a hallmark of
native cardiac stem cells. Descriptions of native cardiac
stem cells, particularly those using Sca-1 as a marker,
have resulted in interest in telomerase expression; Oh
et al. (14) reported that all of the detectable cardiac
telomerase activity was restricted to Sca-1-expressing
cells in myocyte-depleted adult murine cell suspen-
sions. We also identified Sca-11 mTert-GFP cells, al-
though the majority of mTert-GFP1 cells were Sca-12. A
different transgenic model driving reporter gene ex-
pression from an mTert promoter demonstrated a rela-
tionship between Sca-1 and mTert expression (35),
albeit in clonally derived cell lines. Sca-1 is not an
exclusive marker of cardiac stem cells and is expressed
on microvascular endothelial cells (14), and we ac-
knowledge that a proportion of the Sca1, mTert-GFP-
coexpressing population will represent this. These data
highlight the potential use of this mouse in the study of
telomerase biology in the context of cardiac stem cell
populations, although lineage-tracing models will pro-
vide a more definitive understanding of the contribu-
tion they make to various components of the heart. The
finding of mTert-GFP expression in putative cardiac
stem cell populations supports other studies and is
compatible with the assertion that telomerase expres-
sion is a feature of stem cells, germ cells, and tumors.
Although this model allows for the identification of
telomerase-expressing cells with high specificity and
sensitivity, it cannot determine the role of telomerase in
them, nor can the regenerative and replicative compe-
tency of the mTert-GFP populations be determined.
Although all the detectable telomerase activity was
restricted to the mTert-GFP-expressing population, it is
possible that a proportion of this population does not
possess telomerase catalytic activity, and, in fact, ex-
presses it in its signaling role. Regardless of the mech-
anism, telomerase expression has been shown to main-
tain myocyte growth, survival, and turnover (28, 36).
The expression of mTert in a population of mature
cardiomyocytes questions previous assertions that mTert
is restricted to germ, stem, or tumor cells and suggests
a number of hypotheses. It may represent a population
of mature cardiomyocytes capable of replication (37–
39), where mTert acts to maintain telomere length in its
classic role. This is somewhat supported by the higher
frequency of these cells in neonates, in which such a
proliferative potential has been demonstrated (21, 40,
41). It could, however, be the result of GFP perdurance,
identifying cells that have recently differentiated from
more immature cells, perhaps stem cells. This would
still support the utility of mTert-GFP expression in
identifying a population responsible, at least in part, for
cardiomyocyte development and regeneration. Finally,
the expression of mTert in differentiated cardiomyo-
cytes, where cell division is undoubtedly very infre-
quent, may represent its signaling role rather than
telomere maintenance. As such activity is typically re-
lated to pathways of cell survival, this too would be
consistent with the increase in expression following
injury (36, 42). Lineage tracing studies are planned to
examine these hypotheses.
Reduced telomerase activity and reduced telomere
length have been associated with the aging male heart
(11) and heart disease (8, 43). The effect of telomerase
loss in the heart demonstrates a role for the low-level
telomerase activity previously identified in this organ.
As this model demonstrates that telomerase activity is
restricted to the mTert-GFP cell population, it suggests a
role for these cells, or a proportion of them, in the
maintenance of normal cardiac function. We suggest
that this activity arises from subpopulations of a range
of cell types, associated with all components of the
heart, which, although representing only a small pro-
portion, clearly have a fundamental role. Further stud-
ies are planned to dissect their functions in this and
related models, particularly in response to injury.
This work was supported by the British Heart Foundation,
project grant PG/06/110/21521, U.S. National Institutes of
Health grant R01 DK084056 (D.T.B), and the Harvard Stem
Cell Institute (D.T.B). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
REFERENCES
1. Blackburn, E. H. (2005) Telomeres and telomerase: their mech-
anisms of action and the effects of altering their functions. FEBS
Lett. 579, 859–862
2. Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W.,
Steiner, P., Caddle, S. D., Ziaugra, L., Beijersbergen, R. L.,
Davidoff, M. J., Liu, Q., Bacchetti, S., Haber, D. A., and
Weinberg, R. A. (1997) hEST2, the putative human telomerase
catalytic subunit gene, is up-regulated in tumor cells and during
immortalization. Cell 90, 785–795
3. Madonna, R., De Caterina, R., Willerson, J. T., and Geng, Y. J.
Biologic function and clinical potential of telomerase and
associated proteins in cardiovascular tissue repair and regener-
ation. Eur. Heart J. 32, 1190–1196
4. Stewart, S. A., Hahn, W. C., O’Connor, B. F., Banner, E. N.,
Lundberg, A. S., Modha, P., Mizuno, H., Brooks, M. W.,
Fleming, M., Zimonjic, D. B., Popescu, N. C., and Weinberg,
R. A. (2002) Telomerase contributes to tumorigenesis by a
telomere length-independent mechanism. Proc. Natl. Acad. Sci.
U. S. A. 99, 12606–12611
5. Smith, L. L., Coller, H. A., and Roberts, J. M. (2003) Telomerase
modulates expression of growth-controlling genes and en-
hances cell proliferation. Nat. Cell Biol. 5, 474–479
6. Zaccagnini, G., Gaetano, C., Della Pietra, L., Nanni, S., Grasselli,
A., Mangoni, A., Benvenuto, R., Fabrizi, M., Truffa, S., Germani,
A., Moretti, F., Pontecorvi, A., Sacchi, A., Bacchetti, S., Capo-
grossi, M. C., and Farsetti, A. (2005) Telomerase mediates
vascular endothelial growth factor-dependent responsiveness in
a rat model of hind limb ischemia. J. Biol. Chem. 280, 14790–
14798
7. Ahmed, S., Passos, J. F., Birket, M. J., Beckmann, T., Brings, S.,
Peters, H., Birch-Machin, M. A., von Zglinicki, T., and Saretzki,
4839mTert EXPRESSION IN THE HEART
G. (2008) Telomerase does not counteract telomere shortening
but protects mitochondrial function under oxidative stress. J.
Cell Sci. 121, 1046–1053
8. Borges, A., and Liew, C. C. (1997) Telomerase activity during
cardiac development. J. Mol. Cell. Cardiol. 29, 2717–2724
9. Wong, L. S., Oeseburg, H., de Boer, R. A., van Gilst, W. H., van
Veldhuisen, D. J., and van der Harst, P. (2009) Telomere
biology in cardiovascular disease: the TERC-/- mouse as a model
for heart failure and ageing. Cardiovasc. Res. 81, 244–252
10. Oh, H., Taffet, G. E., Youker, K. A., Entman, M. L., Overbeek,
P. A., Michael, L. H., and Schneider, M. D. (2001) Telomerase
reverse transcriptase promotes cardiac muscle cell proliferation,
hypertrophy, and survival. Proc. Natl. Acad. Sci. U. S. A. 98,
10308–10313
11. Leri, A., Quaini, F., Kajstura, J., and Anversa, P. (2001) Myocyte
death and myocyte regeneration in the failing human heart.
Ital. Heart. J. 2(Suppl. 3), 12S–14S
12. Sussman, M. A., and Anversa, P. (2004) Myocardial aging and
senescence: where have the stem cells gone? Annu. Rev. Physiol.
66, 29–48
13. Torella, D., Rota, M., Nurzynska, D., Musso, E., Monsen, A.,
Shiraishi, I., Zias, E., Walsh, K., Rosenzweig, A., Sussman, M. A.,
Urbanek, K., Nadal-Ginard, B., Kajstura, J., Anversa, P., and
Leri, A. (2004) Cardiac stem cell and myocyte aging, heart
failure, and insulin-like growth factor-1 overexpression. Circ.
Res. 94, 514–524
14. Oh, H., Bradfute, S. B., Gallardo, T. D., Nakamura, T., Gaussin,
V., Mishina, Y., Pocius, J., Michael, L. H., Behringer, R. R.,
Garry, D. J., Entman, M. L., and Schneider, M. D. (2003)
Cardiac progenitor cells from adult myocardium: homing,
differentiation, and fusion after infarction. Proc. Natl. Acad. Sci.
U. S. A. 100, 12313–12318
15. Wu, Y. L., Dudognon, C., Nguyen, E., Hillion, J., Pendino, F.,
Tarkanyi, I., Aradi, J., Lanotte, M., Tong, J. H., Chen, G. Q., and
Segal-Bendirdjian, E. (2006) Immunodetection of human te-
lomerase reverse-transcriptase (hTERT) re-appraised: nucleolin
and telomerase cross paths. J. Cell Sci. 119, 2797–2806
16. Armstrong, L., Lako, M., Lincoln, J., Cairns, P. M., and Hole, N.
(2000) mTert expression correlates with telomerase activity
during the differentiation of murine embryonic stem cells.
Mech. Dev. 97, 109–116
17. Breault, D. T., Min, I. M., Carlone, D. L., Farilla, L. G., Ambruzs,
D. M., Henderson, D. E., Algra, S., Montgomery, R. K., Wagers,
A. J., and Hole, N. (2008) Generation of mTert-GFP mice as a
model to identify and study tissue progenitor cells. Proc. Natl.
Acad. Sci. U. S. A. 105, 10420–10425
18. Montgomery, R. K., Carlone, D. L., Richmond, C. A., Farilla, L.,
Kranendonk, M. E., Henderson, D. E., Baffour-Awuah, N. Y.,
Ambruzs, D. M., Fogli, L. K., Algra, S., and Breault, D. T. Mouse
telomerase reverse transcriptase (mTert) expression marks
slowly cycling intestinal stem cells. Proc. Natl. Acad. Sci. U. S. A.
108,, 179–184
19. Stadtfeld, M., Maherali, N., Breault, D. T., and Hochedlinger, K.
(2008) Defining molecular cornerstones during fibroblast to iPS
cell reprogramming in mouse. Cell Stem Cell 2, 230–240
20. Gonzalez-Suarez, E., Geserick, C., Flores, J. M., and Blasco, M. A.
(2005) Antagonistic effects of telomerase on cancer and aging
in K5-mTert transgenic mice. Oncogene 24, 2256–2270
21. Walsh, S., Ponten, A., Fleischmann, B. K., and Jovinge, S.
Cardiomyocyte cell cycle control and growth estimation in
vivo—an analysis based on cardiomyocyte nuclei. Cardiovasc. Res.
86, 365–373
22. Leferovich, J. M., Bedelbaeva, K., Samulewicz, S., Zhang, X. M.,
Zwas, D., Lankford, E. B., and Heber-Katz, E. (2001) Heart
regeneration in adult MRL mice. Proc. Natl. Acad. Sci. U. S. A. 98,
9830–9835
23. Greider, C. W. (1998) Telomerase activity, cell proliferation,
and Cancer Proc. Natl. Acad. Sci. U. S. A. 95, 90–92
24. Endl, E., and Gerdes, J. (2000) The Ki-67 protein: fascinating
forms and an unknown function. Exp. Cell Res. 257, 231–237
25. Juan, G., Traganos, F., James, W. M., Ray, J. M., Roberge, M.,
Sauve, D. M., Anderson, H., and Darzynkiewicz, Z. (1998)
Histone H3 phosphorylation and expression of cyclins A and B1
measured in individual cells during their progression through
G2 and mitosis. Cytometry 32, 71–77
26. Blasco, M. A. (2002) Mouse models to study the role of
telomeres in cancer, aging and DNA repair. Eur. J. Cancer 38,
2222–2228
27. Leri, A., Malhotra, A., Liew, C. C., Kajstura, J., and Anversa, P.
(2000) Telomerase activity in rat cardiac myocytes is age and
gender dependent. J. Mol. Cell. Cardiol. 32, 385–390
28. Leri, A., Barlucchi, L., Limana, F., Deptala, A., Darzynkiewicz,
Z., Hintze, T. H., Kajstura, J., Nadal-Ginard, B., and Anversa, P.
(2001) Telomerase expression and activity are coupled with
myocyte proliferation and preservation of telomeric length in
the failing heart. Proc. Natl. Acad. Sci. U. S. A. 98, 8626–8631
29. Zhu, X., Kumar, R., Mandal, M., Sharma, N., Sharma, H. W.,
Dhingra, U., Sokoloski, J. A., Hsiao, R., and Narayanan, R.
(1996) Cell cycle-dependent modulation of telomerase activity
in tumor cells. Proc. Natl. Acad. Sci. U. S. A. 93, 6091–6095
30. Erusalimsky, J. D., and Skene, C. (2009) Mechanisms of endo-
thelial senescence. Exp. Physiol. 94, 299–304
31. Kurz, D. J., and Erusalimsky, J. D. (2003) Role of telomerase in
human endothelial cell proliferation. Arterioscler. Thromb. Vasc.
Biol. 23, e54
32. Kurz, D. J., Hong, Y., Trivier, E., Huang, H. L., Decary, S., Zang,
G. H., Luscher, T. F., and Erusalimsky, J. D. (2003) Fibroblast
growth factor-2, but not vascular endothelial growth factor,
upregulates telomerase activity in human endothelial cells.
Arterioscler. Thromb. Vasc. Biol. 23, 748–754
33. Liu, T., Nozaki, Y., and Phan, S. H. (2002) Regulation of
telomerase activity in rat lung fibroblasts. Am. J. Respir. Cell Mol.
Biol. 26, 534–540
34. Liu, T., Hu, B., Chung, M. J., Ullenbruch, M., Jin, H., and Phan,
S. H. (2006) Telomerase regulation of myofibroblast differenti-
ation. Am. J. Respir. Cell Mol. Biol. 34, 625–633
35. Tateishi, K., Ashihara, E., Takehara, N., Nomura, T., Honsho, S.,
Nakagami, T., Morikawa, S., Takahashi, T., Ueyama, T., Mat-
subara, H., and Oh, H. (2007) Clonally amplified cardiac stem
cells are regulated by Sca-1 signaling for efficient cardiovascular
regeneration. J. Cell Sci. 120, 1791–1800
36. Leri, A., Franco, S., Zacheo, A., Barlucchi, L., Chimenti, S.,
Limana, F., Nadal-Ginard, B., Kajstura, J., Anversa, P., and
Blasco, M. A. (2003) Ablation of telomerase and telomere loss
leads to cardiac dilatation and heart failure associated with p53
upregulation. EMBO J. 22, 131–139
37. Marino, T. A., Haldar, S., Williamson, E. C., Beaverson, K.,
Walter, R. A., Marino, D. R., Beatty, C., and Lipson, K. E. (1991)
Proliferating cell nuclear antigen in developing and adult rat
cardiac muscle cells. Circ. Res. 69, 1353–1360
38. Kajstura, J., Zhang, X., Reiss, K., Szoke, E., Li, P., Lagrasta, C.,
Cheng, W., Darzynkiewicz, Z., Olivetti, G., and Anversa, P.
(1994) Myocyte cellular hyperplasia and myocyte cellular hyper-
trophy contribute to chronic ventricular remodeling in coro-
nary artery narrowing-induced cardiomyopathy in rats. Circ. Res.
74, 383–400
39. Anversa, P., Palackal, T., Sonnenblick, E. H., Olivetti, G., Meggs,
L. G., and Capasso, J. M. (1990) Myocyte cell loss and myocyte
cellular hyperplasia in the hypertrophied aging rat heart. Circ.
Res. 67, 871–885
40. Beltrami, A. P., Barlucchi, L., Torella, D., Baker, M., Limana, F.,
Chimenti, S., Kasahara, H., Rota, M., Musso, E., Urbanek, K.,
Leri, A., Kajstura, J., Nadal-Ginard, B., and Anversa, P. (2003)
Adult cardiac stem cells are multipotent and support myocardial
regeneration. Cell 114, 763–776
41. Porrello, E. R., Mahmoud, A. I., Simpson, E., Hill, J. A.,
Richardson, J. A., Olson, E. N., and Sadek, H. A. Transient
regenerative potential of the neonatal mouse heart. Science 331,
1078–1080
42. Oh, H., Wang, S. C., Prahash, A., Sano, M., Moravec, C. S.,
Taffet, G. E., Michael, L. H., Youker, K. A., Entman, M. L., and
Schneider, M. D. (2003) Telomere attrition and Chk2 activation
in human heart failure. Proc. Natl. Acad. Sci. U. S. A. 100,
5378–5383
43. Yamaguchi, Y., Nozawa, K., Savoysky, E., Hayakawa, N., Nimura,
Y., and Yoshida, S. (1998) Change in telomerase activity of rat
organs during growth and aging. Exp. Cell Res. 242, 120–127
Received for publication April 24, 2012.
Accepted for publication August 6, 2012.
4840 Vol. 26 December 2012 RICHARDSON ET AL.The FASEB Journal z www.fasebj.org
